HSB 151: Relating to nonopioid drugs on the medical assistance preferred drug list, and health carriers’ development of a pain management access plan

What it does

This bill relates to nonopioid drugs on the medical assistance preferred drug list, and health carriers’ development of a pain management access plan. _____ for an opioid or narcotic drug for the treatment or management of pain on the preferred drug list. Impermissible disadvantaging or discouragement of a nonopioid drug includes designating the nonopioid drug as a nonpreferred drug if any opioid or narcotic is designated as a preferred drug, and establishing more restrictive or extensive utilization controls for a nonopioid drug than the least restrictive or extensive utilization controls applicable to an opioid or narcotic drug.

House subcommittee · named February 11, 2025

• Rep. Judd Lawler (R) · judd.lawler@legis.iowa.gov
• Rep. Brett Barker (R) · brett.barker@legis.iowa.gov
• Rep. Adam Zabner (D) · adam.zabner@legis.iowa.gov

Lobbying · 6 for, 2 against

For: Iowa Behavioral Health Association (IBHA); Iowa Independent Physician Group; Iowa Medical Society; Iowa Mental Health Advocacy; Iowa Physician Assistant Society; Vertex Pharmaceuticals

Against: Cigna Corporate Services, LLC; Federation of Iowa Insurers

In plain words

1. February 11, 2025Filed in the House and sent to the Commerce committee
2. February 11, 2025House subcommittee named: Lawler, Barker and Zabner
3. February 20, 2025Subcommittee recommended passing it